Can metallothionein be a useful molecular marker for selecting hepatocellular carcinoma patients for platinum-based chemotherapy?

被引：4
|
作者：
Doki, Y [1 ]
Monden, M [1 ]
机构：
[1] Osaka Univ, Grad Sch Med, Dept Surg & Clin Oncol, Suita, Osaka 5650871, Japan
来源：
JOURNAL OF GASTROENTEROLOGY | 2004年 / 39卷 / 12期
关键词：
D O I：
10.1007/s00535-004-1508-5
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：1228 / 1229
页数：2
相关论文
共 50 条
  • [21] Molecular mechanisms of platinum-based chemotherapy resistance in ovarian cancer
    Yang, Ling
    Xie, Hong-Jian
    Li, Ying-Ying
    Wang, Xia
    Liu, Xing-Xin
    Mai, Jia
    ONCOLOGY REPORTS, 2022, 47 (04)
  • [22] A single-nucleotide polymorphism as a predictive marker candidate for platinum-based chemotherapy
    Mori, Takahiro
    Nagasaki, Masao
    Ueno, Kazuko
    CANCER SCIENCE, 2025, 116 : 1708 - 1708
  • [23] Reevaluating the role of platinum-based chemotherapy in the evolving treatment landscape for patients with advanced urothelial carcinoma
    Zhang, Tian
    Tan, Alan
    Shah, Amishi Y.
    Iyer, Gopa
    Morris, Valerie
    Michaud, Sebastien
    Sridhar, Srikala S.
    ONCOLOGIST, 2024, 29 (12): : 1003 - 1013
  • [24] Phase II Study of Temozolomide Monotherapy in Patients of Neuroendocrine Carcinoma with Resistant to Platinum-Based Chemotherapy
    Ichikawa, Y.
    Kobayashi, N.
    Tokuhisa, M.
    Goto, A.
    Hiroshima, Y.
    NEUROENDOCRINOLOGY, 2018, 106 : 196 - 196
  • [25] Paclitaxel and carboplatin chemotherapy after platinum-based chemotherapy and pembrolizumab for metastatic urothelial carcinoma
    Furubayashi, Nobuki
    Hori, Yoshifumi
    Morokuma, Futoshi
    Tomoda, Toshihisa
    Negishi, Takahito
    Inoue, Tomohiro
    Kumagai, Masatoshi
    Kuroiwa, Kentaro
    Tokuda, Noriaki
    Nakamura, Motonobu
    MOLECULAR AND CLINICAL ONCOLOGY, 2021, 14 (05)
  • [26] Modification of Platinum-based Systemic Chemotherapy for Advanced Urothelial Carcinoma in Patients With Suboptimal Renal Function
    Hamada, Akihiro
    Sano, Takeshi
    Matsumoto, Keiyu
    Sakatani, Toru
    Nakamura, Kenji
    Sawada, Atsuro
    Akamatsu, Shusuke
    Matsui, Yoshiyuki
    Ogawa, Osamu
    Kobayashi, Takashi
    IN VIVO, 2021, 35 (05): : 2821 - 2829
  • [27] Role of Fyn expression in predicting the sensitivity to platinum-based chemotherapy in patients with ovarian serous carcinoma
    Uchikura, Eijiro
    Fukuda, Takeshi
    Sengiku, Tomoki
    Noda, Takuya
    Awazu, Yuichiro
    Wada, Takuma
    Tasaka, Reiko
    Yamauchi, Makoto
    Yasui, Tomoyo
    Sumi, Toshiyuki
    ONCOLOGY LETTERS, 2024, 28 (05)
  • [28] Efficacy of eribulin therapy in patients with advanced adenoid cystic carcinoma receiving platinum-based chemotherapy
    Sanomachi, T.
    Shimoi, T.
    Kojima, Y.
    Kawachi, A.
    Okuma, H. Sumiyoshi
    Hoshino, M.
    Ito, M.
    Saito, A.
    Kita, S.
    Maejima, A.
    Nishikawa, T.
    Sudo, K.
    Mori, T.
    Yonemori, K.
    ANNALS OF ONCOLOGY, 2024, 35 : S1319 - S1319
  • [29] Expression of bone turnover markers in patients with tuboovarian carcinoma exposed to platinum-based chemotherapy ± bevacizumab
    Kurbacher, C. M.
    Huhmann, A.
    Herz, S.
    Kurbacher, A. T.
    Monreal, K.
    Kurbacher, J. A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 : 750 - 750
  • [30] Treatment of uterine papillary serous carcinoma with platinum-based chemotherapy and paclitaxel
    Vaidya, AP
    Littell, R
    Krasner, C
    Duska, LR
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2006, 16 : 267 - 272
12345